<DOC>
	<DOC>NCT01096940</DOC>
	<brief_summary>To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.</brief_summary>
	<brief_title>Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patients with a clinical diagnosis of T2DM for at least 1 year, treated with any metformin or metformin with one other oral antidiabetic drug (OAD) Body mass index between greater than or equal to 19 and less than or equal to 42 kg/m2 HbA1c greater than 6.5% at enrollment Clinically significant illness or clinically relevant trauma, as judged by the Investigator, within 2 weeks before the first administration of the IP Significant cardiovascular event within the last 6 months prior to enrollment (eg, myocardial infarction/acute coronary syndrome, revascularisation procedure, stroke or transient ischaemic attack) or heart failure New York Heart Association (NYHA) class IIIIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Glucose lowering</keyword>
</DOC>